|
Subject, n
|
68
|
50
|
18
| |
|
Respiratory conditions
|
|
Oxygen flow, L/min
|
3 (2–10)
|
3 (2–10)
|
5 (3–10)
|
0.12
|
|
Serological findings
|
|
White blood cell count, × 103 /μL
|
8.2 (6.6–10.5)
|
8.1 (6.6–10.4)
|
9.6 (6.4–10.5)
|
0.70
|
|
Neutrophils count, × 103 /μL (n = 66)
|
6.78 (4.53–8.65)
|
6.49 (4.49–8.80)
|
7.56 (5.37–8.54)
|
0.68
|
|
Lymphocytes, count, × 103 /μL (n = 66)
|
0.94 (0.69–1.25)
|
1.03 (0.76–1.25)
|
0.66 (0.43–1.35)
|
0.11
|
|
Hemoglobin, g/dL
|
10.8 (9.8–12.5)
|
10.7 (9.8–12.5)
|
11.2 (9.7–12.5)
|
0.95
|
|
Platelet count, × 103 /μL
|
198 (132–267)
|
206 (157–258)
|
179 (88.8–328)
|
0.68
|
|
LDH, IU/L
|
292 (243–379)
|
280 (238–363)
|
345 (269–388)
|
0.21
|
|
BUN, mg/dL
|
21.6 (16.1–32.7)
|
20.2 (15.9–30.6)
|
25.2 (18.5–34.9)
|
0.12
|
|
eGFR, mL/min
|
51.2 (40.8–67.8)
|
60.6 (43.4–71.9)
|
43.2 (29.8–50.9)
|
< 0.05
|
|
CRP, mg/dL
|
8.63 (3.82–13.5)
|
8.54 (3.48–13.2)
|
10.3 (7.77–14.2)
|
0.25
|
|
BALF findings
|
|
Total cell counts in BALF, × 104 /μL
|
5.2 (3.1–9.4)
|
5.1 (3.1–8.8)
|
5.4 (3.9–10.8)
|
0.79
|
|
Neutrophils percentage in BALF, %
|
32.0 (13.1–47.0)
|
23.5 (7.35–38.8)
|
58.8 (41.9–70.4)
|
< 0.05
|
|
Lymphocytes percentage in BALF, %
|
19.5 (8.9–39.9)
|
25.3 (13.0–50.6)
|
8.75 (6.1–12.8)
|
< 0.05
|
|
Clinical courses
|
|
Time from onset to admission, days
|
4 (2–7)
|
4 (2–9)
|
4 (2–5)
|
0.68
|
|
Time from admission to diagnosis of DAH, days
|
1 (0–3)
|
1 (0–3)
|
1 (0–3)
|
0.95
|
|
Treatments
|
|
Invasive ventilation, n
|
38 (56%)
|
22 (44%)
|
16 (89%)
|
< 0.05
|
|
Non-invasive ventilation, n
|
9 (13%)
|
8 (16%)
|
1 (5.6%)
|
0.23
|
|
Administration of antibiotics, n
|
57 (84%)
|
39 (78%)
|
18 (100%)
|
< 0.05
|
|
Administration of corticosteroids, n
|
56 (82%)
|
40 (80%)
|
16 (89%)
|
0.49
|
